Thyroglobulin-guided (131)I ablation in low-risk differentiated thyroid carcinoma: is the yardstick accurate enough?
نویسنده
چکیده
To the Editor: Vaisman and colleagues recently suggested to rule out I ablation in patients with low-risk differentiated thyroid carcinoma (DTC) having negative neck ultrasound, negative thyroglobulin (Tg) antibodies (TgAb), and serum rhTSH-stimulated Tg levels from <1 to 5 ng/mL, measured 3 months after thyroidectomy and selective central compartment neck dissection. In our opinion, however, some critical points concerning Tg measurement need to be further elucidated. In fact, even if measurement of serum Tg levels at the time of I remnant ablation proved to be useful to predict early and long-term outcome of patients, discrepancies between undetectable Tg levels and residual I uptake on a posttreatment whole body scan (PT-WBS) have been reported. In particular, recurrences and metastases on the I PT-WBS scan were proved in 6.3% to 8.5% of patients with an undetectable preablative Tg value. Serum Tg levels that are measured by different methods vary by as much as a factor of 4, even after methods calibration against CRM 457 reference material. Another major problem that hampers accurate Tg measurement is the interference in the Tg assay by TgAb and heterophile antibodies (HAb), resulting in either an underestimation or overestimation of the serum Tg concentration. Immunometric Tg assays may also be subject to a high-dose hook effect, leading to inappropriately normal or low serum Tg values in sera with very high Tg concentrations, which require dilution for accurate measurement. Finally, undetectable serum Tg became detectable in a significant percentage of DTC patients by changing assays, suggesting that in many patients a decrease in immunological reactivity or structural changes of the Tg molecule caused the undetectable Tg levels. Recently, we proved that problems of various kinds may occur with Tg measurement at the time of ablation in up to 1 in 6 patients. Despite extensive laboratory work-up (ie, retesting using different Tg and TgAb immunoassays, recovery test, HAb screening) Tg still was undetectable in about 1 of 5 patients in our series. Considering the sensitivity of both serum Tg and I, an undetectable Tg in the presence of any residual I uptake is highly suspicious for having to deal with pitfalls in Tg measurement. Consequently, the non-negligible risk of a positive PT-WBS in patients with an undetectable Tg level should be considered if Tg is used as a yardstick to rule out I ablation in DTC patients. A single rhTSH-aided I administration (1.1–3.7 GBq) effectively ablates thyroid remnants in most DTC patients, without relevant shortand long-term side effects. The highly sensitive PT-WBS proved to be useful in prognostic stratification of DTC patients and validation of serum Tg as a tumor marker in the long-term DTC follow-up. Additionally, the need for further rhTSH stimulations is becoming virtually absent in low-risk patients treated by thyroid ablation if a second-generation Tg assay is used. Based on these considerations, the reason to perform an rhTSH stimulation every year in 90.4% of low-risk DTC patients to avoid I ablation, as proposed by Vaisman and colleagues, remains at least debatable in our opinion.
منابع مشابه
Evaluation of Treatment of Differentiated Carcinoma of Thyroid.
The treatment of patient with differentiated carcinoma of thyroid consists of three stages, surgery, I 1.1.i ablation and hormone therapy. To avoid the problems mentioned in the article, initially the patient should have thyroid scan, T.1 , T4, thyroglobulin estimation and a chest x-ray, prior to surgery which should be carried out by a competent surgeon, in order that total thyroidectomy can b...
متن کاملHow to manage patients with undetectable thyroglobulin but thyroid residue after radioiodine ablative therapy in differentiated thyroid carcinoma, retreatment or observation?
Introduction:Differentiated thyroid carcinoma (DTC) follow-up after thyroidectomy and radioiodine-ablation is performed mainly by thyroglobulin (Tg), diagnostic iodine-131 whole body scan (DxWBS) and sonography. Some patients with undetectable Tg have thyroid-bed uptake after ablation in whom decision making regarding the need for retreatment is still controversial. Me...
متن کاملEvaluation of response to I-131 ablative therapy in patients with differentiated thyroid carcinoma: A five year retrospective study [Persian]
Differentiated thyroid carcinomas usually show good uptake and response to I-131 ablative treatment. In this study, 90 patients following near total thyroidectomy who were referred to our institute for I-131 therapy are retrospectively studied. The patients are divided in two groups. Group 1 revealed complete ablation after one dose of I-131. Group 2 needed more than one dose of I-131 for...
متن کاملDiagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation
BACKGROUND A diagnostic whole-body scan (WBS) is recommended 6 to 12 months after total thyroidectomy and radioactive iodide ablation in intermediate- or high-risk patients with differentiated thyroid cancer (DTC). The aim of this study was to evaluate the necessity of a diagnostic WBS after radioactive iodide ablation in intermediate-risk patients with DTC. METHODS A total of 438 subjects we...
متن کاملDiagnostic I-131 scintigraphy in patients with differentiated thyroid cancer: no additional value of higher scan dose.
OBJECTIVE After initial treatment with total thyroidectomy and radioiodine ablation, most follow-up protocols for patients with differentiated thyroid carcinoma contain cyclic diagnostic I-131 imaging and serum thyroglobulin measurements. The applied diagnostic I-131 doses vary between 37 and 370 MBq. The aim of this study was to determine the yield of a diagnostic scan with 370 MBq I-131 in pa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Head & neck
دوره 33 9 شماره
صفحات -
تاریخ انتشار 2011